News

10 Aug 2017

PRESS RELEASE: Nicola Sturgeon, First Minister of Scotland, opens REPROCELL European Headquarters in Glasgow

REPROCELL Europe Ltd (REPROCELL), a leading provider of products and services for research in stem cells, drug discovery, human tissues and 3D cell culture and a member of the REPROCELL Group, has opened its European headquarters in Glasgow, UK.
Read More >>

10 Aug 2017

Nicola Sturgeon: interview at the official opening of REPROCELL's Centre for Predictive Drug Discovery (YouTube video)

First Minister Nicola Sturgeon officially opened the new European headquarters of a life sciences company which is set to generate 15 new jobs and safeguard a further three following new investment.
Read More >>

13 May 2016

Latest Proteon and Biopta publication demonstrates Proteon's Vonapanitase effects in human cephalic veins

Proteon Therapeutics Inc., a collaborator of Biopta, today announced publication of additional nonclinical data on Vonapanitase, an investigational drug under development to improve Arteriovenous Fistula (AVF) maturation and patency in chronic kidney disease patients.
Read More >>

21 Apr 2016

Proteon and Biopta publication shows promising nonclinical results on Proteon's Vonapanitase

Proteon Therapeutics Inc. a collaborator of Biopta, today announced publication of additional nonclinical data on investigational drug vonapanitase in peripheral artery disease (PAD).
Read More >>

1 2 3 4 >>

Proteon and Biopta publication shows promising nonclinical results on Proteon's Vonapanitase

21/04/2016

Proteon Therapeutics Announces Publication in the Journal of Cardiovascular Pharmacology of Promising Nonclinical Results for Vonapanitase in Peripheral Artery Disease

Proteon Therapeutics Inc. (Nasdaq:PRTO), a longstanding client of Biopta, is developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases. Proteon today announced publication of additional nonclinical data on investigational drug vonapanitase in peripheral artery disease (PAD). The ex vivo study demonstrated that a single treatment of vonapanitase following angioplasty of excised atherosclerotic human tibial arteries altered artery compliance. Increased compliance is known to correlate with arterial dilation.

The study, titled Recombinant Human Elastase Alters the Compliance of Atherosclerotic Tibial Arteries After Ex Vivo Angioplasty, was published in the Journal of Cardiovascular Pharmacology. Proteons Senior Vice President and Chief Medical Officer, Steven Burke, M.D., is the senior author of the published manuscript. Dr Karen Bingham and Dr Emma Moss of Biopta were co-authors. Proteon's press release can be read here

Live chat by BoldChat